Citation format for publications in TAU (2012-2015)

Published: 2015-12-21

Publications in 2012

1. Guo Y, Lue TF. Introduction to the inaugural issue of TAU. Transl Androl Urol 2012;1(1):1.

2. Breyer BN, McAninch JW. What's new in urological trauma? 2012 update. Transl Androl Urol 2012;1(1):2-3. 

3. Zheng W, Li X, Song G, Zhang Z, Yu W, Gong K, Song Y, Zhang Q, He Z, Guo Y, Zhou L. Comparison of laparoscopic and open cystectomy for bladder cancer: a single center of 110 cases report. Transl Androl Urol 2012;1(1):4-8.

4. Xing N, Guo Y, Yang F, Tian L, Zhang J, Yan Y, Kang N, Xin Z, Niu Y. Laparoscopic simple prostatectomy with prostatic urethra preservation for benign prostatic hyperplasia. Transl Androl Urol 2012;1(1):9-13.

5. Zhang N, Zhang P, Zhang X, Yang Y. The efficacy of resiniferatoxin in prevention of catheter related bladder discomfort in patients after TURP - a pilot, randomized, open study. Transl Androl Urol 2012;1(1):14-18.

6. Gururajan M, Posadas EM, Chung LW. Future perspectives of prostate cancer therapy. Transl Androl Urol 2012;1(1):19-32.

7. Wang J, Li LC. Small RNA and its application in andrology and urology. Transl Androl Urol 2012;1(1):33-43.

8. Tanagho EA. Neuromodulation and neurostimulation: overview and future potential. Transl Androl Urol 2012;1(1):44-49.

9. Chai TC. Coining a new term-Urovesicology: advancing towards a mechanistic understanding of bladder symptoms. Transl Androl Urol 2012;1(1):50-57.

10. Rajfer J. The aging penis: what is it trying to tell us? Transl Androl Urol 2012;1(1):58-60. 

11. Garcia M, Porten S, Lue TF. Commentary on refractory ischemic priapism. Transl Androl Urol 2012;1(1):61-65. 

12. Chi T, Miller J, Stoller ML. Randall plaque versus renal stone? Transl Androl Urol 2012;1(1):66-70.

13. Xu Y, Yang K. Design and construction of translational medicine platform for urologic oncology. Transl Androl Urol 2012;1(1):71-75.

14. Smith AL, Wein AJ. Predicting the future of urodynamics. Transl Androl Urol 2012;1(2):76-77.

15. Lee C, Zhang Q, Zi X, Dash A, Soares MB, Rahmatpanah F, Jia Z, McClelland M, Mercola D. TGF-β mediated DNA methylation in prostate cancer. Transl Androl Urol 2012;1(2):78-88.

16. Kovshilovskaya B, Chi T, Miller J, Stoller ML. Systemic implications of urinary stone disease. Transl Androl Urol 2012;1(2):89-96.

17. Mechlin C, Kogan B. Mast cells, estrogens, and cryptorchidism: A histological based review. Transl Androl Urol 2012;1(2):97-102. 

18. Garaffa G, Antonini G, Gentile V, Ralph DJ. Phalloplasty for the genetic male. Transl Androl Urol 2012;1(2):103-108. 

19. Wu AK, Lue TF. Commentary on high flow, non-ischemic, priapism. Transl Androl Urol 2012;1(2):109-112. 

20. Manger JP, Krupski TL. Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer. Transl Androl Urol 2012;1(2):113-114.

21. Ohlmann CH. Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need? Transl Androl Urol 2012;1(2):115-117. 

22. Wolff JM, Schmid HP. Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab. Transl Androl Urol 2012;1(2):118-119. 

23. Porta C, Ganini C, Paglino C. Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial. Transl Androl Urol 2012;1(2):120-122.

24. Crescentini R, Gupta S, Fishman M. Milestones for development of tivozanib for kidney cancer therapy. Transl Androl Urol 2012;1(2):123-125.

25. Ji KL, Gu LJ. Erectile dysfunction: Doctors’ perspectives on patients’ concerns. Transl Androl Urol 2012;1(2):126-128. 

26. Xin ZC, Ji KL. Translational andrology and urology research: Where is it heading? --Report of the 5th Greatwall Translational Andro-Urology Forum (GTAUF2012). Transl Androl Urol 2012;1(2):129-140.

27. Weinberg AE, Brooks JD. PIVOT and the challenges of localized prostate cancer care. Transl Androl Urol 2012;1(3):141-143. 

28. Lim L, Powles T. New prognostic models in metastatic renal cancer. Transl Androl Urol 2012;1(3):144-145.

29. Shikanov S. Interpretation of PIVOT findings. Transl Androl Urol 2012;1(3):146-147. 

30. Azab S, Osama A, Rafaat M. Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Transl Androl Urol 2012;1(3):148-152.

31. Lee H, Lee YS, Im YJ, Han SW. Vesicoureteral reflux and bladder dysfunction. Transl Androl Urol 2012;1(3):153-159. 

32. Namiki M, Ueno S, Kitagawa Y. Role of hormonal therapy for prostate cancer: perspective from Japanese experiences. Transl Androl Urol 2012;1(3):160-172.

33. Ryu JK, Suh JK. Regenerative technology for future therapy of erectile dysfunction. Transl Androl Urol 2012;1(3):173-180. 

34. Kim SW. Phytotherapy: emerging therapeutic option in urologic disease. Transl Androl Urol 2012;1(3):181-191. 

35. Mihály Z, Panajotu A, Győrffy B. Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy? Transl Androl Urol 2012;1(3):192-193.

36. Desar IM, Mulder SF, Mulders PF, van Herpen CM. The complexity of sunitinib dosing in renal cell cancer patients. Transl Androl Urol 2012;1(3):194-196.

37. Gross-Goupil M, Ravaud A. Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer? Transl Androl Urol 2012;1(3):197-198.

38. Song X. Yinglu Guo: PSA screening test requires wider application in China. Transl Androl Urol 2012;1(4):199-201. 

39. Nozawa M, Uemura H. Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma. Transl Androl Urol 2012;1(4):202-203. 

40. Wada Y, Tanoue K, Takahashi W, Eto M. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. Transl Androl Urol 2012;1(4):204-206.

41. Eskens FA, Haberkorn B. Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor. Transl Androl Urol 2012;1(4):207-208.

42. Zakaria M, Azab S, Rafaat M. Assessment of risk factors of pediatric urolithiasis in Egypt. Transl Androl Urol 2012;1(4):209-215.

43. Coupe N, Harrison M, Chua W, de Souza P. Biomarkers for tyrosine kinase inhibitors in renal cell cancer. Transl Androl Urol 2012;1(4):216-222.

44. Taylor E, Miller J, Chi T, Stoller ML. Complications associated with percutaneous nephrolithotomy. Transl Androl Urol 2012;1(4):223-228. 

45. Yaddanapudi K, Eaton JW. Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up. Transl Androl Urol 2012;1(4):229-233. 

46. Morales A. Conversations in the operating room: history of the development of a promising new compound for the treatment of premature ejaculation. Transl Androl Urol 2012;1(4):234-238.

47. Wu AK, Lue TF. Commentary on the myths of Peyronie’s disease. Transl Androl Urol 2012;1(4):239-244.

48. Ghorbian S. Micro-RNAs, next-generation molecular markers in male infertility field. Transl Androl Urol 2012;1(4):245-246.

Publications in 2013

49. Wang R. Preface. Transl Androl Urol 2013;2(1):1-3. 

50. Shen YJ, Li J, Ye DW. Penile rehabilitation after radical prostatectomy: patients’ attitude and feasibility in China. Transl Androl Urol 2013;2(1):4-9.

51. Li WJ, Yao H, Zhang K, Cai Z, Da J, Xu M, Wang Z. Surgical treatment of Peyronie’s disease by modified 16-dot placation in China. Transl Androl Urol 2013;2(1):10-14.

52. Pendleton CM, Wang R. Peyronie’s disease: current therapy. Transl Androl Urol 2013;2(1):15-23.

53. Burnett AL. Current rehabilitation strategy: clinical evidence for erection recovery after radical prostatectomy. Transl Androl Urol 2013;2(1):24-31. 

54. Stein MJ, DeSouza RA. Anterior urethral stricture review. Transl Androl Urol 2013;2(1):32-38.

55. Levine LA. Peyronie’s disease: contemporary review of non-surgical treatment. Transl Androl Urol 2013;2(1):39-44. 

56. Serefoglu EC, Saitz TR, Trost L, Hellstrom WJ. Premature ejaculation: do we have effective therapy? Transl Androl Urol 2013;2(1):45-53. 

57. Lewis RW. A critical look at descriptive epidemiology of sexual dysfunction in Asia compared to the rest of the world - a call for evidence-based data. Transl Androl Urol 2013;2(1):54-60.

58. Lin H, Wang R. The science of vacuum erectile device in penile rehabilitation after radical prostatectomy. Transl Androl Urol 2013;2(1):61-66.

59. Lee KC, Brock GB. Strategies for maintaining penile size following penile implant. Transl Androl Urol 2013;2(1):67-73. 

60. Incrocci L. Sexual function and male cancer. Transl Androl Urol 2013;2(1):74-81.

61. Abern MR, Tsivian M, Polascik TJ. Refining treatment for the men who need it: lessons from the PIVOT trial. Transl Androl Urol 2013;2(2):82-84.

62. Van Brussel I, Van Craenenbroeck AH, Schrijvers DM, Cools N. Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives? Transl Androl Urol 2013;2(2):85-88.

63. Camarero J, Ruiz S. Immunotherapy in renal cell cancer: the more the merrier? Transl Androl Urol 2013;2(2):89-91. 

64. Heck MM, Gschwend JE, Retz M. Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients. Transl Androl Urol 2013;2(2):92-93. 

65. Li B, Chen G, Wang X. Treatment of failed vasectomy reversal using a microsurgical two-layer anastomosis technique. Transl Androl Urol 2013;2(2):94-98.

66. Zhan P, Ji YN, Yu LK. VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis. Transl Androl Urol 2013;2(2):99-105. 

67. Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol 2013;2(2):106-113.

68. Boyle H. Tivozanib: a novel VGFR inhibitor for kidney cancer. Transl Androl Urol 2013;2(2):114-116. 

69. Pick AM, Cochrane ZR. Identification of biomarkers in pazopanib treated patients with renal cell carcinoma. Transl Androl Urol 2013;2(2):117-118.

70. Antonarakis ES. Enzalutamide: the emperor of all anti-androgens. Transl Androl Urol 2013;2(2):119-120.

71. Hsieh JT, Raj G. Preface. Transl Androl Urol 2013;2(3):121.

72. Silberstein JL, Pal SK, Lewis B, Sartor O. Current clinical challenges in prostate cancer. Transl Androl Urol 2013;2(3):122-136.

73. Eisermann K, Wang D, Jing Y, Pascal LE, Wang Z. Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol 2013;2(3):137-147.

74. Cai C, Yuan X, Balk SP. Androgen receptor epigenetics. Transl Androl Urol 2013;2(3):148-157. 

75. Jin HJ, Kim J, Yu J. Androgen receptor genomic regulation. Transl Androl Urol 2013;2(3):158-177.

76. Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Androl Urol 2013;2(3):178-186. 

77. Liao RS, Ma S, Miao L, Li R, Yin Y, Raj GV. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol 2013;2(3):187-196.

78. Carver BS. Translating insights of AR signaling from mouse models. Transl Androl Urol 2013;2(3):197-201. 

79. Grant CM, Kyprianou N. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Transl Androl Urol 2013;2(3):202-211.

80. Mostaghel EA. Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol 2013;2(3):212-227. 

81. Lo UG, Yang D, Hsieh JT. The role of microRNAs in prostate cancer progression. Transl Androl Urol 2013;2(3):228-241.

82. Moltzahn F, Thalmann GN. Cancer stem cells in prostate cancer. Transl Androl Urol 2013;2(3):242-253.

83. Wu J, Pan D, Chung LW. Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer. Transl Androl Urol 2013;2(3):254-264.

84. Toren PJ, Gleave ME. Novel non-AR therapeutic targets in castrate resistant prostate cancer. Transl Androl Urol 2013;2(3):265-277. 

85. Sanford MT, Greene KL, Carroll PR. The argument for palliative care in prostate cancer. Transl Androl Urol 2013;2(4):278-280. 

86. Tong SF, Low WY, Ismail SB, Trevena L, Wilcock S. Determinants of doctors’ decisions to inquire about sexual dysfunction in Malaysian primary care settings. Transl Androl Urol 2013;2(4):281-290.

87. Hsu GL, Zaid UX, Hsieh CH, Huang SJ. Acupuncture assisted local anesthesia for penile surgeries. Transl Androl Urol 2013;2(4):291-300.

88. Sangkum P, Badr R, Serefoglu EC, Hellstrom WJ. Dapoxetine and the treatment of premature ejaculation. Transl Androl Urol 2013;2(4):301-311. 

89. Odisho AY, Hampson LA, Lue TF. Innovative surgical techniques for managing Peyronie’s disease: a video presentation. Transl Androl Urol 2013;2(4):312-315. 

90. Lue TF, Garcia M. Should perioperative anticoagulation be an integral part of the priapism shunting procedure? Transl Androl Urol 2013;2(4):316-320.

91. Banner L. Virginia Johnson—human sexuality pioneer. Transl Androl Urol 2013;2(4):321-323.

92. Nozawa M, Uemura H. Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma. Transl Androl Urol 2013;2(4):324-327.

93. Xu EX. Professor Christian G. Stief: the role of surgery for prostate cancer with bone metastases. Transl Androl Urol 2013;2(4):328-329.

Publications in 2014

94. Li PS, Goldstein M. Preface. Transl Androl Urol 2014;3(1):1. 

95. Dabaja AA, Wosnitzer MS, Bolyakov A, Schlegel PN, Paduch DA. When to ask male adolescents to provide semen sample for fertility preservation? Transl Androl Urol 2014;3(1):2-8.

96. Dabaja AA, Schlegel PN. Medical treatment of male infertility. Transl Androl Urol 2014;3(1):9-16.

97. Wosnitzer MS. Genetic evaluation of male infertility. Transl Androl Urol 2014;3(1):17-26.

98. Agarwal A, Ong C, Durairajanayagam D. Contemporary and future insights into fertility preservation in male cancer patients. Transl Androl Urol 2014;3(1):27-40. 

99. Revenig L, Leung A, Hsiao W. Ejaculatory physiology and pathophysiology: assessment and treatment in male infertility. Transl Androl Urol 2014;3(1):41-49.

100. Winter AG, Zhao F, Lee RK. Androgen deficiency and metabolic syndrome in men. Transl Androl Urol 2014;3(1):50-58. 

101. Katz MJ, Najari BB, Li PS, Goldstein M. The role of animal models in the study of varicocele. Transl Androl Urol 2014;3(1):59-63. 

102. Velasquez M, Tanrikut C. Surgical management of male infertility: an update. Transl Androl Urol 2014;3(1):64-76. 

103. Katz MJ, Huland DM, Ramasamy R. Multiphoton microscopy: applications in Urology and Andrology. Transl Androl Urol 2014;3(1):77-83. 

104. Osterberg EC, Laudano MA, Li PS. Clinical and investigative applications of Raman spectroscopy in Urology and Andrology. Transl Androl Urol 2014;3(1):84-88.

105. Jamzadeh AE, Laudano MA, Osterberg EC, Goldstein M, Li PS. Microsurgical denervation of the rat spermatic cord and its connection to the diagnosis and treatment of chronic orchialgia: a bench to bedside experience. Transl Androl Urol 2014;3(1):89-93. 

106. Leung A, Mira J, Hsiao W. Updates on sperm retrieval techniques. Transl Androl Urol 2014;3(1):94-101.

107. Gudeloglu A, Brahmbhatt JV, Parekattil SJ. Robotic microsurgery in male infertility and urology—taking robotics to the next level. Transl Androl Urol 2014;3(1):102-112.

108. Barone MA, Li PS, Awori QD, Lee R, Goldstein M. Clinical trials using the Shang Ring device for male circumcision in Africa: a review. Transl Androl Urol 2014;3(1):113-124. 

109. Liu Y, Zhu Y, Li Z. Application of Raman spectroscopy in Andrology: non-invasive analysis of tissue and single cell. Transl Androl Urol 2014;3(1):125-133.

110. Mehta A, Li PS, Goldstein M. Male infertility microsurgical training. Transl Androl Urol 2014;3(1):134-141.

111. Breyer BN, McAninch JW. Preface. Transl Androl Urol 2014;3(2):142.

112. Voelzke BB, Leddy L. The epidemiology of renal trauma. Transl Androl Urol 2014;3(2):143-149.

113. Zaid UB, McAninch JW, Glass AS, Cinman NM, Breyer BN. Presentation, management, and outcomes of complications following prostate cancer therapy. Transl Androl Urol 2014;3(2):150-155.

114. Garcia MM, Christopher NA, De Luca F, Spilotros M, Ralph DJ. Overall satisfaction, sexual function, and the durability of neophallus dimensions following staged female to male genital gender confirming surgery: the Institute of Urology, London U.K. experience. Transl Androl Urol 2014;3(2):156-162.

115. Dielubanza EJ, Han JS, Gonzalez CM. Distal urethroplasty for fossa navicularis and meatal strictures. Transl Androl Urol 2014;3(2):163-169.

116. Raheem OA, Buckley JC. Adjunctive maneuvers to treat urethral stricture: a review of the world literature. Transl Androl Urol 2014;3(2):170-178.

117. Siegel J, Tausch TJ, Simhan J, Morey AF. Innovative approaches for complex penile urethral strictures. Transl Androl Urol 2014;3(2):179-185.

118. Liberman D, Mehus B, Elliott SP. Urinary adverse effects of pelvic radiotherapy. Transl Androl Urol 2014;3(2):186-195.

119. Craig JR, Wallis C, Brant WO, Hotaling JM, Myers JB. Management of adults with prior failed hypospadias surgery. Transl Androl Urol 2014;3(2):196-204. 

120. Santucci RA. The reconstructive urology work force: present and future. Transl Androl Urol 2014;3(2):205-208.

121. Alwaal A, Blaschko SD, McAninch JW, Breyer BN. Epidemiology of urethral strictures. Transl Androl Urol 2014;3(2):209-213.

122. Simhan J, Ramirez D, Hudak SJ, Morey AF. Bladder neck contracture. Transl Androl Urol 2014;3(2):214-220.

123. Warren GJ, Erickson BA. The role of noninvasive testing and questionnaires in urethroplasty follow-up. Transl Androl Urol 2014;3(2):221-226.

124. Chi T, Stoller ML. Kidney stone disease. Transl Androl Urol 2014;3(3):277.

125. Fattah H, Hambaroush Y, Goldfarb DS. Cystine nephrolithiasis. Transl Androl Urol 2014;3(3):228-233. 

126. Chi T, Taylor E, Stoller ML. Treating the cystine stone former presents a singular clinical challenge. Transl Androl Urol 2014;3(3):234.

127. Sorensen MD. Calcium intake and urinary stone disease. Transl Androl Urol 2014;3(3):235-240. 

128. Chi T, Taylor E, Stoller ML. Making sense of dietary calcium and urinary stone disease. Transl Androl Urol 2014;3(3):241. 

129. Canales BK, Gonzalez RD. Kidney stone risk following Roux-en-Y gastric bypass surgery. Transl Androl Urol 2014;3(3):242-249. 

130. Chi T, Taylor E, Stoller ML. Gastric bypass surgery patients warrant special attention for preventing urinary stones. Transl Androl Urol 2014;3(3):250.

131. Chung HJ. The role of Randall plaques on kidney stone formation. Transl Androl Urol 2014;3(3):251-254. 

132. Chi T, Taylor E, Stoller ML. Alexander Randall may have had it right after all. Transl Androl Urol 2014;3(3):255.

133. Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol 2014;3(3):256-276.

134. Chi T, Taylor E, Stoller ML. Reactive oxygen species may unite many mechanisms by which calcium oxalate stones form. Transl Androl Urol 2014;3(3):277.

135. Hyams ES, Matlaga BR. Economic impact of urinary stones. Transl Androl Urol 2014;3(3):278-283. 

136. Chi T, Taylor E, Stoller ML. The days of cost effective management for nephrolithiasis are already upon us. Transl Androl Urol 2014;3(3):284. 

137. Ramaswamy K, Shah O. Metabolic syndrome and nephrolithiasis. Transl Androl Urol 2014;3(3):285-295. 

138. Chi T, Taylor E, Stoller ML. The link between metabolic syndrome and nephrolithiasis: a white whale for understanding urinary stone disease. Transl Androl Urol 2014;3(3):296. 

139. Motamedinia P, Korets R, Badalato G, Gupta M. Perioperative cultures and the role of antibiotics during stone surgery. Transl Androl Urol 2014;3(3):297-301.

140. Chi T, Taylor E, Stoller ML. Looking beyond the guidelines for perioperative antibiotics in nephrolithiasis. Transl Androl Urol 2014;3(3):302. 

141. Nouvenne A, Ticinesi A, Morelli I, Guida L, Borghi L, Meschi T. Fad diets and their effect on urinary stone formation. Transl Androl Urol 2014;3(3):303-312.

142. Chi T, Taylor E, Stoller ML. Moderation may be the best fad diet for urinary stone disease. Transl Androl Urol 2014;3(3):313. 

143. Brotherhood H, Lange D, Chew BH. Advances in ureteral stents. Transl Androl Urol 2014;3(3):314-319. 

144. Chi T, Taylor E, Stoller ML. Ureteral stents are part of an ever-expanding technology horizon. Transl Androl Urol 2014;3(3):320. 

145. Wetherell DR, Ling D, Ow D, Koonjbeharry B, Sliwinski A, Weerakoon M, Papa N, Lawrentschuk N, Bolton DM. Advances in ureteroscopy. Transl Androl Urol 2014;3(3):321-327.

146. Chi T, Taylor E, Stoller ML. Balancing the utility of new technology against cost in urinary stone disease. Transl Androl Urol 2014;3(3):328.

147. Baskin LS, Kogan DB. Pediatric urology focused issue. Transl Androl Urol 2014;3(4):329.

148. Botta S, Cunha GR, Baskin LS. Do endocrine disruptors cause hypospadias? Transl Androl Urol 2014;3(4):330-339. 

149. Kaya C, Radmayr C. The role of pre-operative androgen stimulation in hypospadias surgery. Transl Androl Urol 2014;3(4):340-346. 

150. Dason S, Wong N, Braga LH. The contemporary role of 1 vs. 2-stage repair for proximal hypospadias. Transl Androl Urol 2014;3(4):347-358.

151. Hartigan S, Tasian GE. Unnecessary diagnostic imaging: a review of the literature on preoperative imaging for boys with undescended testes. Transl Androl Urol 2014;3(4):359-364.

152. Mechlin CW, Kogan BA. What lessons can be learned from testicular histology in undescended testes? Transl Androl Urol 2014;3(4):365-369.

153. Hanerhoff BL, Welliver C. Does early orchidopexy improve fertility? Transl Androl Urol 2014;3(4):370-376. 

154. Hollowell JG. Undescended testis and infertility—Is hormonal therapy indicated? Transl Androl Urol 2014;3(4):377-381. 

155. Hussein AA, Tran ND, Smith JF. Fertility preservation for boys and adolescents facing sterilizing medical therapy. Transl Androl Urol 2014;3(4):382-390.

156. Kogan S. The clinical utility of testicular prosthesis placement in children with genital and testicular disorders. Transl Androl Urol 2014;3(4):391-397. 

157. Bogaert GA. Adolescent varicocele: limited indications for treatment during puberty and adolescence. Transl Androl Urol 2014;3(4):398-401. 

158. Glassberg KI. My indications for treatment of the adolescent varicocele (and why?). Transl Androl Urol 2014;3(4):402-412. 

159. Alkaram A, McCullough A. Varicocele and its effect on testosterone: implications for the adolescent. Transl Androl Urol 2014;3(4):413-417.

160. Aggarwal H, Kogan BA. The role of laparoscopy in children with groin problems. Transl Androl Urol 2014;3(4):418-428. 

161. White MD. Pros, cons, and ethics of HPV vaccine in teens—Why such controversy? Transl Androl Urol 2014;3(4):429-434.

162. Guan R, Lei H, Xu Y, Gao Z, Song W, Lin G, Xin Z. Report of 6th Great Wall Translational Andrology and Urology Forum & 7th Asian-Pacific Society of Men’s Health and Anti-aging Meeting (GTAUF2014 & APSMHA2014). Transl Androl Urol 2014;3(4):E1-E4. 

163. Xu EX, Seliman HX. TAU is endorsed by the Genitourinary Medical Association of China International Exchange and Promotive Association for Medical and Health Care (GUA-CPAM): new door open for academic collaboration. Transl Androl Urol 2014;3(4):E5-E6. 

Publications in 2015

164. Simhan J, Morey AF. Focused issue on contemporary management of urethral stricture. Transl Androl Urol 2015;4(1):1. 

165. Maciejewski C, Rourke K. Imaging of urethral stricture disease. Transl Androl Urol 2015;4(1):2-9. 

166. Marshall SD, Raup VT, Brandes SB. Dorsal inlay buccal mucosal graft (Asopa) urethroplasty for anterior urethral stricture. Transl Androl Urol 2015;4(1):10-15.

167. Hudak SJ. Use of overlapping buccal mucosa graft urethroplasty for complex anterior urethral strictures. Transl Androl Urol 2015;4(1):16-21. 

168. Belsante MJ, Selph JP, Peterson AC. The contemporary management of urethral strictures in men resulting from lichen sclerosus. Transl Androl Urol 2015;4(1):22-28.

169. Mori RL, Angermeier KW. Staged urethroplasty in the management of complex anterior urethral stricture disease. Transl Androl Urol 2015;4(1):29-34.

170. Cordon BH, Armenakas NA. Augmented urethroplasty with pseudospongioplasty in the treatment of penile strictures. Transl Androl Urol 2015;4(1):35-40.

171. Bugeja S, Andrich DE, Mundy AR. Non-transecting bulbar urethroplasty. Transl Androl Urol 2015;4(1):41-50.

172. Parker DC, Morey AF, Simhan J. 7-flap perineal urethrostomy. Transl Androl Urol 2015;4(1):51-55. 

173. Siegel JA, Tausch TJ, Morey AF. In situ urethroplasty after artificial urinary sphincter cuff erosion. Transl Androl Urol 2015;4(1):56-59. 

174. Anderson KM, Higuchi TT, Flynn BJ. Management of the devastated posterior urethra and bladder neck: refractory incontinence and stenosis. Transl Androl Urol 2015;4(1):60-65. 

175. Hofer MD, Gonzalez CM. Management of radiation-induced urethral strictures. Transl Androl Urol 2015;4(1):66-71. 

176. Stein DM, Santucci RA. Pro: endoscopic realignment for pelvic fracture urethral injuries. Transl Androl Urol 2015;4(1):72-78.

177. Tausch TJ, Morey AF. Con: bulbomembranous anastomotic urethroplasty for pelvic fracture urethral injuries. Transl Androl Urol 2015;4(1):79-83.

178. Vanni AJ. New frontiers in urethral reconstruction: injectables and alternative grafts. Transl Androl Urol 2015;4(1):84-91. 

179. Incrocci L. Is there a sexual life after treatment of cancer? Transl Androl Urol 2015;4(2):92-94. 

180. Nagele E, Den Oudsten B, Greimel E; on behalf of the EORTC Quality of Life Group. How to evaluate sexual health in cancer patients: development of the EORTC sexual health questionnaire for cancer patients. Transl Androl Urol 2015;4(2):95-102.

181. Canalichio K, Jaber Y, Wang R. Surgery and hormonal treatment for prostate cancer and sexual function. Transl Androl Urol 2015;4(2):103-109. 

182. Gandaglia G, Suardi N, Cucchiara V, Bianchi M, Shariat SF, Roupret M, Salonia A, Montorsi F, Briganti A. Penile rehabilitation after radical prostatectomy: does it work? Transl Androl Urol 2015;4(2):110-123. 

183. Incrocci L. Radiotherapy for prostate cancer and sexual health. Transl Androl Urol 2015;4(2):124-130.

184. Kelly D, Forbat L, Marshall-Lucette S, White I. Co-constructing sexual recovery after prostate cancer: a qualitative study with couples. Transl Androl Urol 2015;4(2):131-138.

185. Gravina GL, Di Sante S, Limoncin E, Mollaioli D, Ciocca G, Carosa E, Sanità P, Di Cesare E, Lenzi A, Jannini EA. Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists. Transl Androl Urol 2015;4(2):139-147.

186. Kadıoğlu A, Ortaç M, Brock G. Pharmacologic and surgical therapies for sexual dysfunction in male cancer survivors. Transl Androl Urol 2015;4(2):148-159.

187. Boswell EN, Dizon DS. Breast cancer and sexual function. Transl Androl Urol 2015;4(2):160-168. 

188. Stabile C, Gunn A, Sonoda Y, Carter J. Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer. Transl Androl Urol 2015;4(2):169-185.

189. Jensen PT, Froeding LP. Pelvic radiotherapy and sexual function in women. Transl Androl Urol 2015;4(2):186-205. 

190. Traa MJ, Roukema JA, De Vries J, Rutten HJ, Langenhoff B, Jansen W, Den Oudsten BL. Biopsychosocial predictors of sexual function and quality of sexual life: a study among patients with colorectal cancer. Transl Androl Urol 2015;4(2):206-217. 

191. Zhou ES, Nekhlyudov L, Bober SL. The primary health care physician and the cancer patient: tips and strategies for managing sexual health. Transl Androl Urol 2015;4(2):218-231.

192. Nelson CJ, Emanu JC, Avildsen I. Couples-based interventions following prostate cancer treatment: a narrative review. Transl Androl Urol 2015;4(2):232-242.

193. Thalmann GN. Focused issue on urological oncology. Transl Androl Urol 2015;4(3):243.

194. von Rundstedt FC, Lerner SP. Bacille-Calmette-Guerin non-responders: how to manage. Transl Androl Urol 2015;4(3):244-253.

195. Roth B, Thalmann GN. Standard cystectomy fits all: truth or myth? Transl Androl Urol 2015;4(3):254-260. 

196. Mathieu R, Bensalah K, Lucca I, Mbeutcha A, Rouprêt M, Shariat SF. Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol 2015;4(3):261-272.

197. Jayaratna IS, Navai N, Dinney CP. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol 2015;4(3):273-282.

198. Leão RR, Richard PO, Jewett MA. Indications for biopsy and the current status of focal therapy for renal tumours. Transl Androl Urol 2015;4(3):283-293.

199. Chopra S, Satkunasivam R, Kundavaram C, Liang G, Gill IS. Outlining the limits of partial nephrectomy. Transl Androl Urol 2015;4(3):294-300.

200. Thomas AZ, Adibi M, Borregales LD, Karam JA, Wood CG. Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol 2015;4(3):301-309.

201. Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol 2015;4(3):310-325. 

202. Radtke JP, Teber D, Hohenfellner M, Hadaschik BA. The current and future role of magnetic resonance imaging in prostate cancer detection and management. Transl Androl Urol 2015;4(3):326-341.

203. Klotz L. Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol 2015;4(3):342-354. 

204. Recine F, Sternberg CN. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol 2015;4(3):355-364. 

205. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 2015;4(3):365-380.

206. Ehrlich Y, Margel D, Lubin MA, Baniel J. Advances in the treatment of testicular cancer. Transl Androl Urol 2015;4(3):381-390.

207. Oyarzábal A, Pérez Y, Molina V, Mas R, Ravelo Y, Jiménez S. D-004 ameliorates phenylephrine-induced urodynamic changes and increased prostate and bladder oxidative stress in rats. Transl Androl Urol 2015;4(4):391-397. 

208. Hsu GL, Hill JW, Chen HS, Huang SJ. Novel pilot films providing indispensable information in pharmaco-cavernosography. Transl Androl Urol 2015;4(4):398-405.

209. Hsu GL, Chen HS, Huang SJ. Does tunica anatomy matter in penile implant? Transl Androl Urol 2015;4(4):406-412. 

210. Goonewardene SS, Persad R. Psychosexual care in prostate cancer survivorship: a systematic review. Transl Androl Urol 2015;4(4):413-420.

211. Salonia A, Castagna G, Capogrosso P, Castiglione F, Briganti A, Montorsi F. Prevention and management of post prostatectomy erectile dysfunction. Transl Androl Urol 2015;4(4):421-437.

212. Ziaee S, Chu GC, Huang JM, Sieh S, Chung LW. Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. Transl Androl Urol 2015;4(4):438-454. 

213. Stark T, Livas L, Kyprianou N. Inflammation in prostate cancer progression and therapeutic targeting. Transl Androl Urol 2015;4(4):455-463.

214. Omiyale AO. Clinicopathological features of primary angiosarcoma of the kidney: a review of 62 cases. Transl Androl Urol 2015;4(4):464-473.

215. Brant WO, Reed-Maldonado A, Lue TF. Injection therapy for Peyronie’s disease: pearls of wisdom. Transl Androl Urol 2015;4(4):474-477. 

216. Foo KT. Diagnosis and treatment of benign prostate hyperplasia in Asia. Transl Androl Urol 2015;4(4):478-483. 

217. Sant GR, Saban R. Interstitial cystitis/bladder pain syndrome (IC/BPS) 2015: Part 1. Transl Androl Urol 2015;4(5):484-485.

218. Yamada Y, Nomiya A, Niimi A, Igawa Y, Ito T, Tomoe H, Takei M, Ueda T, Homma Y. A survey on clinical practice of interstitial cystitis in Japan. Transl Androl Urol 2015;4(5):486-490.

219. Ratner V. The Interstitial Cystitis Association of America: lessons learned over the past 30 years. Transl Androl Urol 2015;4(5):491-498.

220. Meijlink JM. Patient-centred standardization in interstitial cystitis/bladder pain syndrome—a PLEA. Transl Androl Urol 2015;4(5):499-505.

221. Davis NF, Gnanappiragasam S, Thornhill JA. Interstitial cystitis/painful bladder syndrome: the influence of modern diagnostic criteria on epidemiology and on Internet search activity by the public. Transl Androl Urol 2015;4(5):506-511. 

222. Mishra NN. Clinical presentation and treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) in India. Transl Androl Urol 2015;4(5):512-523.

223. Mullins C, Bavendam T, Kirkali Z, Kusek JW. Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder. Transl Androl Urol 2015;4(5):524-533.

224. Charrua A, Pinto R, Birder LA, Cruz F. Sympathetic nervous system and chronic bladder pain: a new tune for an old song. Transl Androl Urol 2015;4(5):534-542.

225. Lamarre NS, Bjorling DE. Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn’t it effective in all patients? Transl Androl Urol 2015;4(5):543-554.

226. Saban R. Angiogenic factors, bladder neuroplasticity and interstitial cystitis—new pathobiological insights. Transl Androl Urol 2015;4(5):555-562.

227. Hurst RE, Greenwood-Van Meerveld B, Wisniewski AB, VanGordon S, Lin H, Kropp BP, Towner RA. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol 2015;4(5):563-571.

228. Janicki JJ, Gruber MA, Chancellor MB. Intravesical liposome drug delivery and IC/BPS. Transl Androl Urol 2015;4(5):572-578.

229. Theoharides TC, Stewart JM. Genitourinary mast cells and survival. Transl Androl Urol 2015;4(5):579-586.

230. Ratner V. Mast cell activation syndrome. Transl Androl Urol 2015;4(5):587-588. 

231. Yang K, Li X, Gao LM. Professor Yinglu Guo awarded Distinguished Career Award at Société Internationale d'Urologie (SIU) 2015. Transl Androl Urol 2015;4(5):589-591.

232. Sant GR, Saban R. Focused issue on interstitial cystitis/bladder pain syndrome (IC/BPS) 2015: Part 2. Transl Androl Urol 2015;4(6):592-593. 

233. Victal ML, D’Ancona CA, Junqueira RG, Carlos da Silva D, Oliveira HC, de Moraes Lopes MH. Test-retest reliability and discriminant validity for the Brazilian version of “The Interstitial Cystitis Symptom Index and Problem Index” and “Pelvic Pain and Urgency/Frequency (PUF) Patient Symptom Scale” instruments. Transl Androl Urol 2015;4(6):594-599.

234. Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective? Transl Androl Urol 2015;4(6):600-604. 

235. Parsons CL. How does interstitial cystitis begin? Transl Androl Urol 2015;4(6):605-610. 

236. Gupta P, Gaines N, Sirls LT, Peters KM. A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care. Transl Androl Urol 2015;4(6):611-619.

237. Flores-Carreras O, González-Ruiz MI, Martínez-Espinoza CJ, Monroy-Rodríguez F, Zaragoza-Torres RM. Interstitial cystitis/painful bladder syndrome: diagnostic evaluation and therapeutic response in a private urogynecology unit. Transl Androl Urol 2015;4(6):620-623. 

238. Ens G, Garrido GL. Role of cystoscopy and hydrodistention in the diagnosis of interstitial cystitis/bladder pain syndrome. Transl Androl Urol 2015;4(6):624-628.

239. Cvach K, Rosamilia A. Review of intravesical therapies for bladder pain syndrome/interstitial cystitis. Transl Androl Urol 2015;4(6):629-637. 

240. Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol 2015;4(6):638-642. 

241. Fariello JY, Moldwin RM. Similarities between interstitial cystitis/bladder pain syndrome and vulvodynia: implications for patient management. Transl Androl Urol 2015;4(6):643-652. 

242. Pang R, Ali A. The Chinese approach to complementary and alternative medicine treatment for interstitial cystitis/bladder pain syndrome. Transl Androl Urol 2015;4(6):653-661.

243. Atchley MD, Shah NM, Whitmore KE. Complementary and alternative medical therapies for interstitial cystitis: an update from the United States. Transl Androl Urol 2015;4(6):662-667. 

244. Arora HC, Shoskes DA. The enigma of men with interstitial cystitis/bladder pain syndrome. Transl Androl Urol 2015;4(6):668-676. 

245. Colaco M, Evans R. Current guidelines in the management of interstitial cystitis. Transl Androl Urol 2015;4(6):677-683. 

246. Gao LM, Seliman HX. Professor Run Wang: can erectile dysfunction be cured? Transl Androl Urol 2015;4(6):684-685.